1. Home
  2. KYMR vs EVR Comparison

KYMR vs EVR Comparison

Compare KYMR & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kymera Therapeutics Inc.

KYMR

Kymera Therapeutics Inc.

HOLD

Current Price

$122.17

Market Cap

9.0B

Sector

Health Care

ML Signal

HOLD

Logo Evercore Inc.

EVR

Evercore Inc.

SELL

Current Price

$291.55

Market Cap

9.7B

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
KYMR
EVR
Founded
2015
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
9.7B
IPO Year
2020
2006

Fundamental Metrics

Financial Performance
Metric
KYMR
EVR
Price
$122.17
$291.55
Analyst Decision
Strong Buy
Buy
Analyst Count
24
11
Target Price
$139.83
★ $332.20
AVG Volume (30 Days)
★ 745.8K
529.2K
Earning Date
10-29-2026
10-28-2026
Dividend Yield
N/A
★ 1.37%
EPS Growth
N/A
★ 54.74
EPS
N/A
★ 9.56
Revenue
$39,211,000.00
★ $3,880,084,000.00
Revenue This Year
$167.19
$20.37
Revenue Next Year
N/A
$13.13
P/E Ratio
★ N/A
$27.20
Revenue Growth
N/A
★ 29.49
52 Week Low
$55.66
$245.47
52 Week High
$130.05
$388.71

Technical Indicators

Market Signals
Indicator
KYMR
EVR
Relative Strength Index (RSI) 64.76 68.82
Support Level $110.64 $280.02
Resistance Level $128.95 $300.24
Average True Range (ATR) 5.03 9.80
MACD 1.50 3.27
Stochastic Oscillator 96.51 95.43

Price Performance

Historical Comparison
KYMR
EVR

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

About EVR Evercore Inc.

Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. Evercore operates globally, with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance-sheet lending, allowing it to compete with larger, bulge-bracket banks.

Share on Social Networks: